CLL patients in stage 0 showed a higher percentage of intermediate monocytes (CD14+CD16+SLAN−) (median (IQR) 6.54 (3.87–8.30)%) as compared to both patients with stage I/II (median (IQR) 5.12 (3.29–8.58)%) and III/IV (median (IQR) 4.63 (4.04–5.98)%), but the difference was not significant (Figure 3B). This evidence concerns the gene SECISBP2L and B-cell chronic lymphocytic leukemia.